Mediterranean-style diet in pregnant women with metabolic risk factors (ESTEEM): A pragmatic multicentre randomised trial.


Journal

PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360

Informations de publication

Date de publication:
07 2019
Historique:
received: 13 02 2019
accepted: 19 06 2019
entrez: 24 7 2019
pubmed: 25 7 2019
medline: 20 12 2019
Statut: epublish

Résumé

Pregnant women with metabolic risk factors are at high risk of complications. We aimed to assess whether a Mediterranean-style diet reduces adverse pregnancy outcomes in high-risk women. We conducted a multicentre randomised trial in 5 maternity units (4 in London and 1 in Birmingham) between 12 September 2014 and 29 February 2016. We randomised inner-city pregnant women with metabolic risk factors (obesity, chronic hypertension, or hypertriglyceridaemia) to a Mediterranean-style diet with high intake of nuts, extra virgin olive oil, fruits, vegetables, nonrefined grains, and legumes; moderate to high consumption of fish; low to moderate intake of poultry and dairy products; low intake of red and processed meat; and avoidance of sugary drinks, fast food, and food rich in animal fat versus usual care. Participants received individualised dietary advice at 18, 20, and 28 weeks' gestation. The primary endpoints were composite maternal (gestational diabetes or preeclampsia) and composite offspring (stillbirth, small for gestational age, or admission to neonatal care unit) outcomes prioritised by a Delphi survey. We used an intention-to-treat (ITT) analysis with multivariable models and identified the stratification variables and prognostic factors a priori. We screened 7,950 and randomised 1,252 women. Baseline data were available for 593 women in the intervention (93.3% follow-up, 553/593) and 612 in the control (95.6% follow-up, 585/612) groups. Over a quarter of randomised women were primigravida (330/1,205; 27%), 60% (729/1,205) were of Black or Asian ethnicity, and 69% (836/1,205) were obese. Women in the intervention arm consumed more nuts (70.1% versus 22.9%; adjusted odds ratio [aOR] 6.8, 95% confidence interval [CI] 4.3-10.6, p ≤ 0.001) and extra virgin olive oil (93.2% versus 49.0%; aOR 32.2, 95% CI 16.0-64.6, p ≤ 0.001) than controls; increased their intake of fish (p < 0.001), white meat (p < 0.001), and pulses (p = 0.05); and reduced their intake of red meat (p < 0.001), butter, margarine, and cream (p < 0.001). There was no significant reduction in the composite maternal (22.8% versus 28.6%; aOR 0.76, 95% CI 0.56-1.03, p = 0.08) or composite offspring (17.3% versus 20.9%; aOR 0.79, 95% CI 0.58-1.08, p = 0.14) outcomes. There was an apparent reduction in the odds of gestational diabetes by 35% (aOR 0.65, 95% CI 0.47-0.91, p = 0.01) but not in other individual components of the composite outcomes. Mothers gained less gestational weight (mean 6.8 versus 8.3 kg; adjusted difference -1.2 Kg, 95% CI -2.2 to -0.2, p = 0.03) with intervention versus control. There was no difference in any of the other maternal and offspring complications between both groups. When we pooled findings from the Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes (ESTEEM) trial with similar trials using random effects meta-analysis, we observed a significant reduction in gestational diabetes (odds ratio [OR] 0.67, 95% CI 0.53-0.84, I2 = 0%), with no heterogeneity (2 trials, 2,397 women). The study's limitations include the use of participant reported tools for adherence to the intervention instead of objective biomarkers. A simple, individualised, Mediterranean-style diet in pregnancy did not reduce the overall risk of adverse maternal and offspring complications but has the potential to reduce gestational weight gain and the risk of gestational diabetes. ClinicalTrials.gov NCT02218931.

Sections du résumé

BACKGROUND
Pregnant women with metabolic risk factors are at high risk of complications. We aimed to assess whether a Mediterranean-style diet reduces adverse pregnancy outcomes in high-risk women.
METHODS AND FINDINGS
We conducted a multicentre randomised trial in 5 maternity units (4 in London and 1 in Birmingham) between 12 September 2014 and 29 February 2016. We randomised inner-city pregnant women with metabolic risk factors (obesity, chronic hypertension, or hypertriglyceridaemia) to a Mediterranean-style diet with high intake of nuts, extra virgin olive oil, fruits, vegetables, nonrefined grains, and legumes; moderate to high consumption of fish; low to moderate intake of poultry and dairy products; low intake of red and processed meat; and avoidance of sugary drinks, fast food, and food rich in animal fat versus usual care. Participants received individualised dietary advice at 18, 20, and 28 weeks' gestation. The primary endpoints were composite maternal (gestational diabetes or preeclampsia) and composite offspring (stillbirth, small for gestational age, or admission to neonatal care unit) outcomes prioritised by a Delphi survey. We used an intention-to-treat (ITT) analysis with multivariable models and identified the stratification variables and prognostic factors a priori. We screened 7,950 and randomised 1,252 women. Baseline data were available for 593 women in the intervention (93.3% follow-up, 553/593) and 612 in the control (95.6% follow-up, 585/612) groups. Over a quarter of randomised women were primigravida (330/1,205; 27%), 60% (729/1,205) were of Black or Asian ethnicity, and 69% (836/1,205) were obese. Women in the intervention arm consumed more nuts (70.1% versus 22.9%; adjusted odds ratio [aOR] 6.8, 95% confidence interval [CI] 4.3-10.6, p ≤ 0.001) and extra virgin olive oil (93.2% versus 49.0%; aOR 32.2, 95% CI 16.0-64.6, p ≤ 0.001) than controls; increased their intake of fish (p < 0.001), white meat (p < 0.001), and pulses (p = 0.05); and reduced their intake of red meat (p < 0.001), butter, margarine, and cream (p < 0.001). There was no significant reduction in the composite maternal (22.8% versus 28.6%; aOR 0.76, 95% CI 0.56-1.03, p = 0.08) or composite offspring (17.3% versus 20.9%; aOR 0.79, 95% CI 0.58-1.08, p = 0.14) outcomes. There was an apparent reduction in the odds of gestational diabetes by 35% (aOR 0.65, 95% CI 0.47-0.91, p = 0.01) but not in other individual components of the composite outcomes. Mothers gained less gestational weight (mean 6.8 versus 8.3 kg; adjusted difference -1.2 Kg, 95% CI -2.2 to -0.2, p = 0.03) with intervention versus control. There was no difference in any of the other maternal and offspring complications between both groups. When we pooled findings from the Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes (ESTEEM) trial with similar trials using random effects meta-analysis, we observed a significant reduction in gestational diabetes (odds ratio [OR] 0.67, 95% CI 0.53-0.84, I2 = 0%), with no heterogeneity (2 trials, 2,397 women). The study's limitations include the use of participant reported tools for adherence to the intervention instead of objective biomarkers.
CONCLUSIONS
A simple, individualised, Mediterranean-style diet in pregnancy did not reduce the overall risk of adverse maternal and offspring complications but has the potential to reduce gestational weight gain and the risk of gestational diabetes.
TRIAL REGISTRATION
ClinicalTrials.gov NCT02218931.

Identifiants

pubmed: 31335871
doi: 10.1371/journal.pmed.1002857
pii: PMEDICINE-D-19-00518
pmc: PMC6650045
doi:

Banques de données

ClinicalTrials.gov
['NCT02218931']

Types de publication

Journal Article Multicenter Study Pragmatic Clinical Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1002857

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

BMJ Open. 2016 Oct 21;6(10):e013495
pubmed: 27798035
Best Pract Res Clin Obstet Gynaecol. 2015 Apr;29(3):309-19
pubmed: 25702971
PLoS One. 2017 Oct 19;12(10):e0185873
pubmed: 29049303
Eur J Clin Nutr. 2014 Jan;68(1):8-13
pubmed: 24084515
Ann Intern Med. 2014 Jan 7;160(1):1-10
pubmed: 24573661
N Engl J Med. 2013 Aug 15;369(7):676-7
pubmed: 23944307
Br J Nutr. 2012 Jan;107(1):135-45
pubmed: 21733314
BMJ. 2017 Jul 19;358:j3119
pubmed: 28724518
BMC Med. 2013 Sep 19;11:207
pubmed: 24050803
CMAJ. 2007 Apr 10;176(8):1113-20
pubmed: 17420495
Health Technol Assess. 2017 Aug;21(41):1-158
pubmed: 28795682
Pregnancy Hypertens. 2012 Apr 1;2(2):72-83
pubmed: 22745921
Am J Clin Nutr. 2000 May;71(5 Suppl):1242S-8S
pubmed: 10799397
J Diabetes Res. 2015;2015:731434
pubmed: 25961055
Int J Behav Nutr Phys Act. 2016 Nov 29;13(1):124
pubmed: 27894316
BJOG. 2016 Jan;123(2):190-8
pubmed: 26841002
Diabetologia. 2012 May;55(5):1319-28
pubmed: 22322921
Public Health Nutr. 2009 Sep;12(9A):1629-34
pubmed: 19689832
Br J Nutr. 2012 Oct 28;108(8):1399-409
pubmed: 22348517
Contemp Clin Trials Commun. 2017 Mar 29;6:72-77
pubmed: 29740638
Circulation. 2017 Feb 14;135(7):633-643
pubmed: 28193797
Nutr Metab Cardiovasc Dis. 2013 Jul;23(7):677-83
pubmed: 22633793
Nutr J. 2013 Feb 19;12:26
pubmed: 23421854
Am J Clin Nutr. 2010 Jun;91(6):1659-66
pubmed: 20410088
Lancet Diabetes Endocrinol. 2015 Oct;3(10):767-77
pubmed: 26165396
Obesity (Silver Spring). 2008 Jun;16(6):1413-20
pubmed: 18421273
BMC Public Health. 2015 May 02;15:457
pubmed: 25934496
Diabetes Care. 2010 Mar;33(3):676-82
pubmed: 20190296
J Acad Nutr Diet. 2014 May;114(5):734-60
pubmed: 24631111
BMJ. 2014 Feb 10;348:g1285
pubmed: 24513442
N Engl J Med. 2013 Apr 4;368(14):1279-90
pubmed: 23432189
Oxid Med Cell Longev. 2017;2017:6723931
pubmed: 28883903
J Nutr. 2011 Jun;141(6):1140-5
pubmed: 21508208
Nutr Diabetes. 2018 Apr 25;8(1):22
pubmed: 29695712
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2186-91
pubmed: 16990564
Nutr J. 2015 Apr 22;14:40
pubmed: 25897837
Cancer. 1981 Mar 1;47(5 Suppl):1121-5
pubmed: 6263443

Auteurs

Bassel H Al Wattar (B)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Warwick Medical School, University of Warwick, Coventry, United Kingdom.

Julie Dodds (J)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Anna Placzek (A)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Lee Beresford (L)

Pragmatic Clinical Trials Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Eleni Spyreli (E)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Amanda Moore (A)

Diabetes & Nutritional Sciences Division, Faculty of Life Sciences & Medicine, King's College, London, United Kingdom.

Francisco J Gonzalez Carreras (FJ)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Frances Austin (F)

Maternity Dietetic Service, Women's and Children's Services, Barts NHS Trust, London, United Kingdom.

Nilaani Murugesu (N)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Tessa J Roseboom (TJ)

Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, the Netherlands.
Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, the Netherlands.

Maira Bes-Rastrollo (M)

Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.
CIBERobn, Instituto de Salud Carlos III, Madrid, Spain.
IDISNA, Navarra Institute for Health Research, Pamplona, Spain.

Graham A Hitman (GA)

Barts Diabetes and Obesity Research Group, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Richard Hooper (R)

Pragmatic Clinical Trials Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.

Khalid S Khan (KS)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Multidisciplinary Evidence Synthesis Hub (mEsh), Blizard Institute, Barts and the London School of Medicine, Queen Mary University London, London, United Kingdom.

Shakila Thangaratinam (S)

BARC (Barts Research Centre for Women's Health), Women's Health Research Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Multidisciplinary Evidence Synthesis Hub (mEsh), Blizard Institute, Barts and the London School of Medicine, Queen Mary University London, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH